Aigen Investment Management LP Makes New Investment in Boston Scientific Co. (NYSE:BSX)

Aigen Investment Management LP acquired a new position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 6,761 shares of the medical equipment provider's stock, valued at approximately $567,000.

A number of other hedge funds have also made changes to their positions in BSX. CRA Financial Services LLC raised its position in shares of Boston Scientific by 4.3% during the 3rd quarter. CRA Financial Services LLC now owns 2,841 shares of the medical equipment provider's stock worth $238,000 after purchasing an additional 117 shares during the last quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA boosted its position in Boston Scientific by 9.7% during the 3rd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,352 shares of the medical equipment provider's stock worth $115,000 after acquiring an additional 119 shares during the period. Ashton Thomas Securities LLC increased its stake in shares of Boston Scientific by 1.3% during the third quarter. Ashton Thomas Securities LLC now owns 9,968 shares of the medical equipment provider's stock valued at $835,000 after acquiring an additional 129 shares during the period. CVA Family Office LLC raised its position in Boston Scientific by 7.4% in the second quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider's stock worth $147,000 after acquiring an additional 131 shares in the last quarter. Finally, Jacobsen Capital Management boosted its holdings in Boston Scientific by 4.9% during the third quarter. Jacobsen Capital Management now owns 2,820 shares of the medical equipment provider's stock worth $236,000 after buying an additional 133 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

BSX stock traded down $0.84 during trading on Thursday, reaching $87.93. The company's stock had a trading volume of 2,795,739 shares, compared to its average volume of 6,054,284. The company has a market capitalization of $129.59 billion, a P/E ratio of 73.36, a price-to-earnings-growth ratio of 2.61 and a beta of 0.79. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. The company's fifty day moving average is $85.03 and its 200-day moving average is $79.33. Boston Scientific Co. has a 1 year low of $53.56 and a 1 year high of $89.30.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. The firm had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. Boston Scientific's revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period last year, the firm posted $0.50 earnings per share. On average, research analysts expect that Boston Scientific Co. will post 2.46 earnings per share for the current fiscal year.

Insider Activity at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the completion of the sale, the executive vice president now owns 34,748 shares of the company's stock, valued at approximately $2,913,967.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Michael F. Mahoney sold 162,777 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the firm's stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.86, for a total value of $585,594.38. Following the transaction, the executive vice president now owns 34,748 shares of the company's stock, valued at approximately $2,913,967.28. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 309,270 shares of company stock worth $26,196,718. Company insiders own 0.50% of the company's stock.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent analyst reports. Evercore ISI lifted their target price on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Raymond James lifted their target price on Boston Scientific from $91.00 to $94.00 and gave the company a "strong-buy" rating in a research note on Wednesday, September 4th. Canaccord Genuity Group upped their target price on shares of Boston Scientific from $88.00 to $98.00 and gave the company a "buy" rating in a research report on Monday, October 21st. Bank of America boosted their price objective on shares of Boston Scientific from $90.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, October 22nd. Finally, Citigroup lifted their target price on Boston Scientific from $92.00 to $98.00 and gave the stock a "buy" rating in a report on Thursday, October 24th. Four equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.